[go: up one dir, main page]

CA2368215A1 - Compositions et procedes pour le traitement de diabetes - Google Patents

Compositions et procedes pour le traitement de diabetes Download PDF

Info

Publication number
CA2368215A1
CA2368215A1 CA002368215A CA2368215A CA2368215A1 CA 2368215 A1 CA2368215 A1 CA 2368215A1 CA 002368215 A CA002368215 A CA 002368215A CA 2368215 A CA2368215 A CA 2368215A CA 2368215 A1 CA2368215 A1 CA 2368215A1
Authority
CA
Canada
Prior art keywords
insulin
diabetes
cells
luteolin
brickellia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002368215A
Other languages
English (en)
Inventor
Randy H. Ziegler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2368215A1 publication Critical patent/CA2368215A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5085—Supracellular entities, e.g. tissue, organisms of invertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)

Abstract

L'invention concerne des produits extraits de Brickellia californica et des flavonoïdes isolés, dont l'apigénine, la lutéoline, la quercétine et dihydroxykaemférol, purifiés provenant de Brickellia californica, qui sont utiles pour le traitement de diabètes. Les produits extraits et des flavonoïdes peuvent être utilisés en alternance dans le traitement des diabètes insulinodépendant et non insulinodépendant car ces substances entraînent la baisse sensible du glucose.
CA002368215A 1999-04-05 2000-04-04 Compositions et procedes pour le traitement de diabetes Abandoned CA2368215A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12782499P 1999-04-05 1999-04-05
US60/127,824 1999-04-05
PCT/US2000/008957 WO2000059522A1 (fr) 1999-04-05 2000-04-04 Compositions et procedes pour le traitement de diabetes

Publications (1)

Publication Number Publication Date
CA2368215A1 true CA2368215A1 (fr) 2000-10-12

Family

ID=22432145

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002368215A Abandoned CA2368215A1 (fr) 1999-04-05 2000-04-04 Compositions et procedes pour le traitement de diabetes

Country Status (7)

Country Link
EP (1) EP1169047A1 (fr)
JP (1) JP2002541116A (fr)
AU (1) AU780233B2 (fr)
BR (1) BR0009592A (fr)
CA (1) CA2368215A1 (fr)
MX (1) MXPA01010037A (fr)
WO (1) WO2000059522A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020068704A1 (en) * 1999-04-05 2002-06-06 Ziegler Randy H. Compositions and methods for treatment of diabetes
ES2340363T3 (es) * 2000-12-21 2010-06-02 The Quigley Corporation Metodo y composicion para el tratamiento de la neuropatia diabetica.
US6555573B2 (en) 2000-12-21 2003-04-29 The Quigley Corporation Method and composition for the topical treatment of diabetic neuropathy
KR20040048407A (ko) * 2001-09-06 2004-06-09 시녹스, 인크. 3-데옥시플라보노이드에 의한 ｔ-림프구 활성화의 억제 및그의 관련 치료법
WO2003094928A1 (fr) 2002-05-06 2003-11-20 Diakron Pharmaceuticals, Inc. Compositions pharmaceutiques permettant de reduire la glycemie et les taux de cholesterol sanguin
US7083813B2 (en) 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
AU2004253579B2 (en) 2003-07-01 2010-12-23 Biomol International L.P. Sirt1 modulators for manipulating cells/organism lifespan/stress response
US20050171027A1 (en) * 2003-12-29 2005-08-04 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
WO2006138418A2 (fr) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Amelioration de la performance cognitive avec des activateurs de sirtuine
JP2008007452A (ja) * 2006-06-28 2008-01-17 Ajinomoto Co Inc 膵β細胞保護剤
US8287677B2 (en) 2008-01-31 2012-10-16 Kimberly-Clark Worldwide, Inc. Printable elastic composite
JP5594719B2 (ja) * 2010-01-06 2014-09-24 国立大学法人神戸大学 筋肉の糖取り込み促進剤

Also Published As

Publication number Publication date
AU4196400A (en) 2000-10-23
MXPA01010037A (es) 2003-07-14
BR0009592A (pt) 2002-01-08
WO2000059522A1 (fr) 2000-10-12
JP2002541116A (ja) 2002-12-03
EP1169047A1 (fr) 2002-01-09
AU780233B2 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
Jabri et al. Role of laxative and antioxidant properties of Malva sylvestris leaves in constipation treatment
AU780233B2 (en) Compositions and methods for treatment of diabetes
US6391854B1 (en) Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes
US20020068704A1 (en) Compositions and methods for treatment of diabetes
Knoll Satietin: A highly potent anorexogenic substance in human serum
US6416794B1 (en) Methods and compositions for treating cataracts using substances derived from yeast or saltbush
JP2005500263A (ja) 糖尿病の予防及び治療を目的とする医薬草本化合物
KR101845862B1 (ko) 특발성 폐섬유증의 치료 또는 예방을 위한 약학적 조성물
Ingle The functional interrelationship of the anterior pituitary and the adrenal cortex
Mahood Effects of Pimpinella anisum oil extract on some biochemical parameters in mice experimentally induced for human polycystic ovary syndrome
Binita et al. The therapeutic potential of Syzygium cumini seeds in diabetes mellitus
Hastings et al. Melatonin and the brain in photoperiodic mammals
Yokoyama Hypothalamic and hormonal control of the photoperiodically induced vernal functions in the White-crowned Sparrow, Zonotrichia leucophrys gambelii: 1. The effects of hypothalamic lesions and exogenous hormones
Bilchik et al. Amelioration of cholinergic-induced pancreatitis with a selective cholecystokinin receptor antagonist
US20100297267A1 (en) Compositions for diabetes treatment and prophylaxis
KR20070069566A (ko) 티모사포닌 ａ―ⅲ가 함유된 조성물의 용도 및 이의제조방법
Umamaheswari et al. Effect of the fractions of Coccinia grandis on naphthalene-induced cataractogenesis in rats
US8865237B2 (en) Method of preparing dialysed extract of fenugreek seeds which induces hypoglycemia, mediated, in part, via stimulation of insulin signaling pathway
Debas et al. Geranyl-geranyl acetone: a novel stimulant of secretin release in the dog
KR20150135746A (ko) 대극 추출물 또는 이의 정제 분획물을 유효성분으로 함유하는 당뇨 합병증 및 혈관 부종 예방 및 치료용 약학적 조성물
Bloom et al. Enteropancreatic axis
Cuber Secretory activity of the endocrine, I and M cells of the gut
OA21752A (fr) Composition pharmaceutique ou diététique comprenant un mélange des extraits aqueux d'Origanum Majorana, d'Origanum Vulgare et de Salvia Rosmarinus (Rosmarinus officinalis) pour traiter le diabète.
Pozdeev et al. Biosynthesis of melatonin during early postnatal ontogeny in pineal gland of healthy rats and animals with hereditary retinal degeneration
Sagen Transplantation strategies for the treatment of pain

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead